

This is a translation of the Swedish press release published 2022-12-20

Nomination committee in Neola Medical AB (publ) elected

The chairman of the board in Neola Medical AB (publ) have assembled a nomination committee. The nomination committee will develop proposals for the 2023 annual general meeting regarding the meeting chairman, board members, chairman of the board and auditor. The nomination committee will also draw up proposals regarding compensation for board members and auditors.

The nomination committee appointed before the 2023 annual general meeting in Neola Medical consists of the following people:

Anders Pettersson, appointed by ANMIRO AB Pär Josefsson, appointed by Pär Josefsson Hites Jina, appointed by LMK Forward AB

The nomination committee's proposal will be presented in the notice to the annual general meeting that will take place on May 17, 2023. The proposal will also be available on the company's website www.neolamedical.com.

Shareholders who wish to submit proposals to the nomination committee can contact the chairman of the nomination committee Pär Josefsson via e-mail: <u>par@josefsson.com</u>. Please note that the deadline for submitting proposals is 17 January 2023.

For further information, contact:

Hanna Sjöström, CEO Neola Medical, e-mail: <u>hanna.sjostrom@neolamedical.com</u>

Neola Medical AB (publ) develops medical technology device for continuous monitoring of preterm born infants' lungs. Immediate detection of complications provides the possibility of early treatment and improved health care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 as a wholly owned subsidiary of Gasporox AB (publ) under the name GPX Medical AB. The company is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more on www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.